Laubach reports receiving commercial research grants from Celgene, Millennium ,
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases, Authors' Contributions Conception, vol.1, pp.585-98, 2007. ,
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations, Leukemia, vol.20, pp.807-820, 2006. ,
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma, Haematologica, vol.98, pp.1586-92, 2013. ,
Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases, Leukemia, vol.12, pp.960-969, 1998. ,
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, vol.102, pp.2562-2569, 2003. ,
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma, Blood, vol.116, pp.3227-3264, 2010. ,
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, vol.10, pp.5094-100, 2004. ,
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem, vol.108, pp.19-24, 2006. ,
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood, vol.101, pp.1530-1534, 2003. ,
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, vol.96, pp.2943-50, 2000. ,
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma, Leukemia, vol.28, pp.993-1000, 2014. ,
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans, Blood, vol.121, pp.2975-87, 2013. ,
Lenalidomide enhances anti-myeloma cellular immunity, Cancer Immunol Immunother, vol.62, pp.39-49, 2013. ,
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002. ,
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, vol.8, pp.190-198, 2006. ,
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin Cancer Res, vol.11, pp.2947-53, 2005. ,
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, vol.28, pp.682-690, 2011. ,
Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, vol.13, pp.2151-2158, 2007. ,
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, vol.66, pp.3381-3386, 2006. ,
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, vol.49, pp.2233-2275, 2013. ,
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8 þ T lymphocytes in human non-small cell lung cancer, Cell Mol Immunol, vol.7, pp.389-95, 2010. ,
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, Blood, vol.116, pp.2286-94, 2010. ,
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, vol.11, pp.3887-95, 1992. ,
Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma, J Immunol, vol.190, pp.5620-5628, 2013. ,
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine, J Immunother, vol.34, pp.409-427, 2011. ,
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma, Leukemia, vol.27, pp.464-72, 2013. ,
B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice, Oncol Rep, vol.30, pp.2442-2450, 2013. ,
PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008. ,
A new analysis of allogeneic interactions, Aust J Exp Biol Med Sci, vol.53, pp.27-42, 1975. ,
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, vol.5, pp.1365-1374, 1999. ,
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, vol.192, pp.1027-1061, 2000. ,
Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin Proc, vol.78, pp.21-33, 2003. ,
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A, vol.99, pp.12293-12300, 2002. ,
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proc Natl Acad Sci U S A, vol.101, pp.17174-17183, 2004. ,
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer, Cancer Res, vol.73, pp.6900-6912, 2013. ,
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors, Cancer Res, vol.73, pp.3591-603, 2013. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, pp.2443-54, 2012. ,
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, pp.134-178, 2013. ,
, Oncology Clinics of North America. Melanoma. Preface. Hematol Oncol Clin North Am, vol.28, pp.xiii-xiv, 2014.
PD-L1 expression in non-clear cell renal cell carcinoma, Ann Oncol, vol.25, pp.2178-84, 2014. ,
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment, Eur J Haematol, vol.92, pp.195-203, 2014. ,
The role of B7 family molecules in hematologic malignancy, Blood, vol.121, pp.734-778, 2013. ,
Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo, Clin Cancer Res, vol.20, pp.2674-83, 2014. ,
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, Leukemia, vol.28, pp.2367-75, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00981338
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, vol.372, pp.311-320, 2015. ,
Gr-1 þ CD115 þ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res, vol.66, pp.1123-1154, 2006. ,
Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas, J Invest Dermatol, vol.132, pp.1239-1285, 2012. ,
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer, Clin Immunol, vol.129, pp.471-81, 2008. ,
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma, Clin Cancer Res Güllü Görgün, vol.2014, pp.4607-4618, 2015. ,